Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novartis : INTENT TO SOLE source

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 06:03pm CEST

Notice Type: CONTRACT AWARD

Posted Date: 03-OCT-17

Office: Bureau of Medicine and Surgery

Location: NAVAL MEDICAL CENTER SAN DIEGO

Office Address: DEPARTMENT OF THE NAVY, BUREAU OF MEDICINE AND SURGERY, NAVAL MEDICAL CENTER SAN DIEGO, BLDG 134800 BOB WILSON DRIVE SAN DIEGO, CA 92134-5000

Classification Code: Q - Medical services

Subject: INTENT TO SOLE source

Solicitation Number: N0025917N0100

Award Number: N0025917P0670

Award Date: 082817

Awardee: ALCON LABORATORIES, INC.

Archive: 10042017

Contact: ARATIYA K. LUSK, EMAIL [email protected]

Internet Link: https://www.fbo.gov/spg/DON/BUMED/N00259/Awards/N0025917P0670.html

Copyright (c) 2017 Federal Information & News Dispatch, Inc., source Federal Documents

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
05:18pNOVARTIS : Adlai Nortye Announce Global License Agreement for Buparlisib BKM120
AQ
05:11pSwiss, German drugmakers join U.S. price freeze
RE
01:33pNOVARTIS : Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, ..
AQ
01:02pNOVARTIS AG : Free Post Earnings Research Report: Novartis’ Net Sales Jumped 7%;..
AC
11:36aNOVARTIS : Patent Issued for Prostaglandin Conjugates and Derivatives for Treati..
AQ
11:26aAEQUUS PHARMACEUTICALS : Extends and Enhances Commercial Agreement to Promote Vi..
AQ
11:18aNOVARTIS : New Asthma Findings Reported from Novartis (Description of Baseline C..
AQ
06:38aNOVARTIS : Patent Issued for Ophthalmic Illumination Profiles and Associated Dev..
AQ
07/19NOVARTIS : Research Data from Novartis Update Understanding of Ankylosing Spondy..
AQ
07/19NOVARTIS : Researchers from Novartis Report Recent Findings in Translational Med..
AQ
More news
News from SeekingAlpha
08:00a3 THINGS IN BIOTECH, JULY 20 : The Specter Haunts This Small Biotech 
05:02aMUSTANG BIO : A Differentiated CAR-T Innovator With Multiple Unlocking Catalysts 
02:36aAllergan's Big Win For 12-Week Wet AMD Dosing With Abicipar May Be Enough To .. 
07/19Galapagos and MorphoSys out-license MOR106 to Novartis for up to $1.1B 
07/19Amazon Tops $900 Billion In Market Value (Wall Street Breakfast Podcast) 
Financials ($)
Sales 2018 51 864 M
EBIT 2018 12 767 M
Net income 2018 9 611 M
Debt 2018 13 675 M
Yield 2018 3,64%
P/E ratio 2018 16,23
P/E ratio 2019 20,15
EV / Sales 2018 4,24x
EV / Sales 2019 4,08x
Capitalization 206 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 90,2 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-1.75%206 001
JOHNSON & JOHNSON-8.53%342 779
PFIZER3.98%220 295
ROCHE HOLDING LTD.-5.90%203 399
MERCK AND COMPANY11.09%169 328
AMGEN10.27%127 577